Skip to main content
. 2020 Jun 30;10:913. doi: 10.3389/fonc.2020.00913

Figure 2.

Figure 2

Analysis of markers before treatment and the best response to nivolumab or durvalumab monotherapy. All patients were divided into two groups according to PLR (A), albumin (B), and PD-L1 (C) expression before treatment.